Orly Vardeny

2012–2025 年に発表

114
論文数
24,132
被引用数
57
h 指数
102
i10 指数

被引用数

Orly Vardeny の年別被引用数1996 年: 被引用 1 件2003 年: 被引用 3 件2005 年: 被引用 2 件2008 年: 被引用 1 件2013 年: 被引用 6 件2014 年: 被引用 11 件2015 年: 被引用 10 件2016 年: 被引用 17 件2017 年: 被引用 19 件2018 年: 被引用 30 件2019 年: 被引用 91 件2020 年: 被引用 1,290 件2021 年: 被引用 872 件2022 年: 被引用 839 件2023 年: 被引用 1,091 件2024 年: 被引用 2,203 件2025 年: 被引用 1,308 件2026 年: 被引用 40 件1997〜2002 年は被引用が無いため表示していません2004 年は被引用が無いため表示していません2006〜2007 年は被引用が無いため表示していません2009〜2012 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,883 件、この内訳の 20.1%イギリス: 引用元論文 1,058 件、この内訳の 7.4%イタリア: 引用元論文 914 件、この内訳の 6.4%中国: 引用元論文 766 件、この内訳の 5.3%カナダ: 引用元論文 659 件、この内訳の 4.6%ドイツ: 引用元論文 642 件、この内訳の 4.5%フランス: 引用元論文 528 件、この内訳の 3.7%オランダ: 引用元論文 499 件、この内訳の 3.5%スペイン: 引用元論文 440 件、この内訳の 3.1%オーストラリア: 引用元論文 366 件、この内訳の 2.6%スウェーデン: 引用元論文 361 件、この内訳の 2.5%日本: 引用元論文 349 件、この内訳の 2.4%
0%20.1%その他 33.9%

分野

  • Medicine89.2%
  • Biochemistry, Genetics and Molecular Biology4.5%
  • Engineering1.6%
  • Computer Science0.8%
  • Health Professions0.6%
  • Immunology and Microbiology0.6%
  • その他2.7%

トピック

  • Heart Failure Treatment and Management10.6%
  • Cardiovascular Function and Risk Factors8.1%
  • COVID-19 Clinical Research Studies7.5%
  • Diabetes Treatment and Management5.5%
  • Long-Term Effects of COVID-194.1%
  • SARS-CoV-2 and COVID-19 Research3.2%
  • その他61%

共著者

全論文

検索で開く
  1. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , С. Н. Терещенко, Jorge Thierer, Muthiah Vaduganathan, Orly Vardeny, Subodh Verma, Vinh Pham, Ulrica Wilderäng, Natalia Zaozerska, Erasmus Bachus, Daniel Lindholm, Magnus Petersson, Anna Maria Langkilde - New England Journal of Medicine 2022 被引用: 2,658

  2. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2022 被引用: 2,590

  3. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2022 被引用: 2,066

  4. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Petar Seferović, Randall C. Starling, John R. Teerlink, Orly Vardeny, Kazuhiro Yamamoto, Clyde W. Yancy, Jian Zhang, Shelley Zieroth - European Journal of Heart Failure 2021 被引用: 1,556

  5. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gustavs Latkovskis, Alex Pui‐Wai Lee, Gerard C.M. Linssen, Guillermo Llamas-Esperón, Vyacheslav Mareev, Felipe A. Martínez, Vojtěch Melenovský, Béla Merkely, Savina Nodari, Mark C. Petrie, Clara Saldarriaga, José Francisco Kerr Saraiva, Naoki Sato, Morten Schou, Kavita Sharma, Richard W. Troughton, Jacob A. Udell, Heikki Ukkonen, Orly Vardeny, Subodh Verma, Dirk von Lewinski, Л. Г. Воронков, Mehmet Birhan Yılmaz, Shelley Zieroth, James Lay‐Flurrie, Ilse van Gameren, Flaviana Amarante, Peter Kolkhof, Prabhakar Viswanathan - New England Journal of Medicine 2024 被引用: 709

  6. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2022 被引用: 881

  7. Universal Definition and Classification of Heart Failure

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Petar SeferoviĆ, Randall C. Starling, John R. Teerlink, Orly Vardeny, Kazuhiro Yamamoto, Clyde Yancy, Jian Zhang, Shelley Zieroth - Journal of Cardiac Failure 2021 被引用: 929

  8. Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation

    著者: , , , , , , , - JACC Heart Failure 2022 被引用: 284

  9. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2022 被引用: 361

  10. Recognition and Initial Management of Fulminant Myocarditis

    著者: , , , , , , , , , - Circulation 2020 被引用: 596

  11. 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kim K. Birtcher, Joaquin E. Cigarroa, Lisa de las Fuentes, Anita Deswal, Dave L. Dixon, Lee A. Fleisher, Federico Gentile, Zachary D. Goldberger, Bülent Görenek, Norrisa Haynes, Adrian F. Hernandez, Mark A. Hlatky, José A. Joglar, W Schuyler Jones, Joseph E. Marine, Daniel B. Mark, Debabrata Mukherjee, Latha Palaniappan, Mariann R. Piano, Tanveer Rab, Erica S. Spatz, Jacqueline E. Tamis‐Holland, Duminda N. Wijeysundera, Y. Joseph Woo - Journal of Cardiac Failure 2022 被引用: 406

  12. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2019 被引用: 370

  13. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2022 被引用: 150

  14. Association of Influenza Vaccination With Cardiovascular Risk

    著者: , , , , , , - JAMA Network Open 2022 被引用: 172

  15. Kidney Function and Outcomes in Patients Hospitalized With Heart Failure

    著者: , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2021 被引用: 197

  16. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Orly Vardeny, Subodh Verma, Pham Nguyễn Vinh, Ulrica Wilderäng, Natalia Zaozerska, Daniel Lindholm, Magnus Petersson, John J.V. McMurray - JACC Heart Failure 2022 被引用: 165

  17. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US

    著者: , , , , , , , , , , , , , , , , , , - JAMA Cardiology 2023 被引用: 108

  18. Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alex Pui‐Wai Lee, Gerard C.M. Linssen, Guillermo Llamas-Esperón, Vyacheslav Mareev, Felipe A. Martínez, Vojtěch Melenovský, Béla Merkely, Savina Nodari, Mark C. Petrie, Clara Saldarriaga, José Francisco Kerr Saraiva, Naoki Sato, Morten Schou, Kavita Sharma, Richard W. Troughton, Jacob A. Udell, Heikki Ukkonen, Orly Vardeny, Subodh Verma, Dirk von Lewinski, Л. Г. Воронков, Mehmet Birhan Yılmaz, Shelley Zieroth, James Lay‐Flurrie, Ilse van Gameren, Flaviana Amarante, Prabhakar Viswanathan, John J.V. McMurray - European Journal of Heart Failure 2024 被引用: 62

  19. Deprescribing for Community-Dwelling Older Adults: a Systematic Review and Meta-analysis

    著者: , , , , , , , , - Journal of General Internal Medicine 2020 被引用: 248

  20. Potential Effects of Coronaviruses on the Cardiovascular System

    著者: , , , - JAMA Cardiology 2020 被引用: 1,872

  21. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2022 被引用: 77

  22. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - Circulation Heart Failure 2022 被引用: 124

  23. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril

    著者: , , , , , , , , , , - JAMA Cardiology 2016 被引用: 215

  24. Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

    著者: , , , , , , , , , , , , , , , , , , , - European Heart Journal 2021 被引用: 154